CD19 and leukemia: The pioneering trails of CAR-T-CD19 therapy in patients with lymphoma or leukemia, resulting in FDA approval of two distinct anti-CD19 CAR T cell products for the treatment of both acute lymphoblastic leukaemia and diffuse large B cell lymphoma (136–138).